BLUE vs. EDIT

Last updated Apr 1, 2026

Compare and contrast key facts about bluebird bio, Inc. (BLUE) and Editas Medicine, Inc. (EDIT).

Performance

BLUE vs. EDIT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in bluebird bio, Inc. (BLUE) and Editas Medicine, Inc. (EDIT). The values are adjusted to include any dividend payments, if applicable.

BLUE vs. EDIT - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
BLUE bluebird bio, Inc.	0.00%	-40.41%	-69.78%	-80.06%	-30.73%	-64.35%	-50.69%	-11.54%	-44.30%	188.65%
EDIT Editas Medicine, Inc.	20.49%	61.42%	-87.46%	14.21%	-66.59%	-62.13%	136.78%	30.15%	-25.97%	89.34%

Fundamentals

Total Revenue (TTM) BLUE : $103.95M EDIT : $40.52M
Gross Profit (TTM) BLUE : $28.19M EDIT : $39.72M
EBITDA (TTM) BLUE : -$115.82M EDIT : $0.00

Returns By Period

BLUE

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

EDIT

• 1D: 10.76%
• 1M: 12.27%
• YTD: 20.49%
• 6M: -28.82%
• 1Y: 112.93%
• 3Y*: -30.16%
• 5Y*: -43.48%
• 10Y*: -23.69%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

BLUE vs. EDIT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

EDIT

EDIT Risk / Return Rank: 75
EDIT Sharpe Ratio Rank: 78
EDIT Sortino Ratio Rank: 82
EDIT Omega Ratio Rank: 75
EDIT Calmar Ratio Rank: 73
EDIT Martin Ratio Rank: 68

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BLUE vs. EDIT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for bluebird bio, Inc. (BLUE) and Editas Medicine, Inc. (EDIT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	BLUE	EDIT	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	1.16	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.47	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	-0.28	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	-0.21	—

Correlation

The correlation between BLUE and EDIT is 0.46, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

BLUE vs. EDIT - Dividend Comparison

Neither BLUE nor EDIT has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

Drawdown Indicators

	BLUE	EDIT	Difference
Max Drawdown Largest peak-to-trough decline	—	-98.92%	—
Max Drawdown (1Y) Largest decline over 1 year	—	-59.88%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-98.66%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-98.92%	—
Current Drawdown Current decline from peak	—	-97.27%	—
Average Drawdown Average peak-to-trough decline	—	-61.98%	—
Ulcer Index Depth and duration of drawdowns from previous peaks	—	31.49%	—

Volatility

Volatility by Period

	BLUE	EDIT	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	31.71%	—
Volatility (6M) Calculated over the trailing 6-month period	—	60.26%	—
Volatility (1Y) Calculated over the trailing 1-year period	—	98.42%	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	—	93.19%	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	—	83.41%	—

Financials